Advertisement
Screener

Stoke Therapeutics, Inc. (STOK) Overview

Stoke Therapeutics, Inc. (STOK) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.93; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.79; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.65; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.40; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$21.25$24.15$27.44$31.18$35.44$40.272025-11-062026-11-06$3.20$5.31$8.81$14.63$24.27$40.272021-11-082026-11-06$3.20$5.99$11.20$20.95$39.19$73.302019-06-192026-11-06$3.20$5.99$11.20$20.95$39.19$73.302019-06-192026-11-06$3.20$5.99$11.20$20.95$39.19$73.302019-06-192026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$26.52
Previous close
$25.88
Change
$0.64
Change (%)
2.47%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

STOK
-18.46%
S&P 500
(m)

1 year

STOK
+4.65%
S&P 500
(m)

3 years

STOK
+556.85%
S&P 500
(m)

5 years

STOK
+1.49%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.93

-1.01-0.240.531.312.0831 Mar 2025: estimate (m); actual 1.9031 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.4030 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.6530 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.7931 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.9330 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.93(m)(m)
1 Jan 202631 Mar 2026(m)-0.79(m)(m)
1 Jul 202530 Sept 2025(m)-0.65(m)(m)
1 Apr 202530 Jun 2025(m)-0.40(m)(m)
1 Jan 202531 Mar 2025(m)1.90(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.12

-2.68-2.00-1.31-0.630.0631 Dec 2021: estimate (m); actual -2.3431 Dec 2021(m)31 Dec 2022: estimate (m); actual -2.6031 Dec 2022(m)31 Dec 2023: estimate (m); actual -2.3831 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.6531 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.1231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.12(m)(m)
1 Jan 202431 Dec 2024(m)-1.65(m)(m)
1 Jan 202331 Dec 2023(m)-2.38(m)(m)
1 Jan 202231 Dec 2022(m)-2.60(m)(m)
1 Jan 202131 Dec 2021(m)-2.34(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 9.32M ■ Earnings -61.62M — Profit margin -660.78%

-70.29M-4133.2%-40.42M-2875.4%-10.56M-1617.5%19.30M-359.7%30 Sept 2025: revenue 10.63M; earnings -38.35M; profit margin -360.68%30 Sept 202531 Dec 2025: revenue 1.40M*; earnings -57.93M*; profit margin -4132.24%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 6.23M; earnings -50.00M; profit margin -802.75%31 Mar 202630 Jun 2026: revenue 9.32M; earnings -61.62M; profit margin -660.78%30 Jun 2026

31 Dec 2025 ■ Revenue 184.42M ■ Earnings -6.88M — Profit margin -3.73%

-139.39M-1193.5%-19.89M-796.6%99.61M-399.6%219.11M-2.7%31 Dec 2022: revenue 12.40M; earnings -101.07M; profit margin -814.73%31 Dec 202231 Dec 2023: revenue 8.78M; earnings -104.70M; profit margin -1192.47%31 Dec 202331 Dec 2024: revenue 36.55M; earnings -88.98M; profit margin -243.42%31 Dec 202431 Dec 2025: revenue 184.42M; earnings -6.88M; profit margin -3.73%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$26.52(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$26.52High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning STOK

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-207.90M
Profit margin
-753.60%
Return on assets · 12 month
-53.41%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
170.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
863.29K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-11.37%*
Total return · month
-18.15%*
Total return · quarter
-20.10%*
Total return · half year
-21.22%*
Total return · year to date
-18.46%*
Total return · 1 year
4.65%*
Total return · 3 years
556.85%*
Total return · 5 years
1.49%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$27.59M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Stoke Therapeutics, Inc. Overview

View more →

(m)

(m)

SEC CIK
1623526
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
45 WIGGINS AVENUE, BEDFORD, Massachusetts, 01730, United States
Fiscal year end
1231
Phone
781-430-8200

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Xencor Inc (XNCR)United States$1.776B-7.33
Septerna, Inc. (SEPN)United States$1.783B-63.01